J9286 Glofitamab-gxbm - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Glofitamab-gxbm

Brand Name:

Columvi

Strength:

2.5mg

HCPCS:

J9286

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

CD20, CD3

Oral (Y/N):

No

FDA Approval Year:

2023

FDA Discontinuation Year:

CMS Effective Date:

Dec. 7, 2023

CMS Discontinuation Date:

Status:

In Use